ProShares Ultra NASDAQ Biotechnology
26 hedge funds and large institutions have $7.07M invested in ProShares Ultra NASDAQ Biotechnology in 2020 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 6 closing their positions.
80% more call options, than puts
Call options by funds: $4M | Put options by funds: $2.23M
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
0% more funds holding
Funds holding: 26 → 26 (0)
6.17% less ownership
Funds ownership: 11.94% → 5.77% (-6.2%)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
69% less capital invested
Capital invested by funds: $22.9M → $7.07M (-$15.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
+$628K |
| 2 |
TI
Trexquant Investment
Stamford,
Connecticut
|
+$315K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$287K |
| 4 |
Morgan Stanley
New York
|
+$95.4K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$94.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$5.64M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.9M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$1.54M |
| 4 |
Jane Street
New York
|
-$1.36M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.14M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GWM
26
Geneos Wealth Management
Englewood,
Colorado
| $7K | -$5.64M | -101,270 | -100% |
|
|
BG
27
Bellevue Group
Kuesnacht,
Switzerland
| – | -$1.54M | -25,000 | Closed |
|
|
28
Jane Street
New York
| – | -$1.36M | -24,327 | Closed |
|
29
LPL Financial
San Diego,
California
| – | -$226K | -3,660 | Closed |
|
|
CG
30
Cutler Group
San Francisco,
California
| – | -$51.6K | -926 | Closed |
|
31
BNP Paribas Financial Markets
Paris,
France
| – | -$10.3K | -167 | Closed |
|
|
IA
32
IFP Advisors
Tampa,
Florida
| – | -$8K | -120 | Closed |
|
BIB Hedge Fund Activity: Q1 2020 in Review
26 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q1 2020, worth a combined $7.07M — down 69% from $22.9M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new BIB positions and 6 closed out — a net gain of 2 holders — while 4 added to existing stakes and 7 trimmed.
The largest buyer was Toth Financial Advisory, adding an estimated $628K. The largest seller was Geneos Wealth Management, cutting an estimated $5.64M.
- 26 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $7.07M of ProShares Ultra NASDAQ Biotechnology stock for Q1 2020, down 69% quarter-over-quarter.
- 8 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q1 2020 and 6 closed out, a net change of +2 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q1 2020 was Toth Financial Advisory, an estimated $628K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q1 2020 was Geneos Wealth Management, an estimated $5.64M sold.
Based on aggregated 13F filings for Q1 2020.